Literature DB >> 19394699

Demethylating treatment suppresses natural killer cell cytolytic activity.

Xiao-ning Gao1, Ji Lin, Li-li Wang, Li Yu.   

Abstract

NK cells as a component of the innate immune system provide a first line of defense against viral infections and malignancies. Killer immunoglobulin-like receptors (KIRs) are a polymorphic gene family expressed on NK cells. The crucial role of DNA methylation in determining the variegated expression pattern of KIRs has recently been reported. In this study the direct effect of DNA demethylating treatment on human NK cell cytotoxicity was analyzed. In a human NK cell line NK-92MI, inhibitory KIR genes exhibited characteristic epigenetic repression, whose promoter regions are densely methylated. Treatment of NK-92MI cells with methyltransferase inhibitor 5-azacytidine significantly increased the expression levels of inhibitory KIRs and strongly suppressed their cytolytic activity against human K562 leukemic cells. Cytolytic activity of human polyclonal NK cells was also suppressed upon 5-azacytidine-treatment. The suppression of NK cell cytotoxicity was associated with 5-azacytidine-induced overexpression of inhibitory KIRs and impaired granzyme B and perforin release by these cells. The results demonstrate for the first time that demethylating treatment can suppress NK cell cytolytic activity. The aberrant methylation patterns of KIR genes during NK cell differentiation and maturation may have importance for its abnormal function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19394699     DOI: 10.1016/j.molimm.2009.02.033

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  22 in total

1.  Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice.

Authors:  Jeannette Cany; Mieke W H Roeven; Janneke S Hoogstad-van Evert; Willemijn Hobo; Frans Maas; Rosalia Franco Fernandez; Nicole M A Blijlevens; Walter J van der Velden; Gerwin Huls; Joop H Jansen; Nicolaas P M Schaap; Harry Dolstra
Journal:  Blood       Date:  2017-11-14       Impact factor: 22.113

2.  DNA methylation-mediated Siglec-7 regulation in natural killer cells via two 5' promoter CpG sites.

Authors:  Hsin-Ting Huang; Shih-Chi Su; Tzeon-Jye Chiou; Yen-Hsi Lin; Yi-Chen Shih; Yu-Xuan Wu; Ting-Hsi Fan; Yuh-Ching Twu
Journal:  Immunology       Date:  2020-03-05       Impact factor: 7.397

3.  DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells.

Authors:  Alba Fernández-Sánchez; Aroa Baragaño Raneros; Reyes Carvajal Palao; Ana B Sanz; Alberto Ortiz; Francisco Ortega; Beatriz Suárez-Álvarez; Carlos López-Larrea
Journal:  Epigenetics       Date:  2012-12-12       Impact factor: 4.528

4.  5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.

Authors:  May Kung Sutherland; Changpu Yu; Martha Anderson; Weiping Zeng; Nico van Rooijen; Eric L Sievers; Iqbal S Grewal; Che-Leung Law
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

Review 5.  Immunological effects of hypomethylating agents.

Authors:  Katherine E Lindblad; Meghali Goswami; Christopher S Hourigan; Karolyn A Oetjen
Journal:  Expert Rev Hematol       Date:  2017-07-03       Impact factor: 2.929

6.  Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes.

Authors:  Cristina Gattazzo; Antonella Teramo; Marta Miorin; Elisa Scquizzato; Anna Cabrelle; Mirna Balsamo; Carlo Agostini; Elena Vendrame; Monica Facco; Maria Paola Albergoni; Livio Trentin; Massimo Vitale; Gianpietro Semenzato; Renato Zambello
Journal:  Haematologica       Date:  2010-04-21       Impact factor: 9.941

Review 7.  Epigenetic regulation of natural killer cell memory.

Authors:  Colleen M Lau; Gabriela M Wiedemann; Joseph C Sun
Journal:  Immunol Rev       Date:  2021-12-14       Impact factor: 12.988

Review 8.  Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.

Authors:  Julia Stomper; John Charles Rotondo; Gabriele Greve; Michael Lübbert
Journal:  Leukemia       Date:  2021-05-06       Impact factor: 11.528

9.  Molecular study of the perforin gene in familial hematological malignancies.

Authors:  Rim El Abed; Violaine Bourdon; Ilia Voskoboinik; Halima Omri; Yosra Ben Youssef; Mohamed Adnene Laatiri; Laetitia Huiart; François Eisinger; Laetitia Rabayrol; Marc Frenay; Paul Gesta; Liliane Demange; Hélène Dreyfus; Valérie Bonadona; Catherine Dugast; Hélène Zattara; Laurence Faivre; Monia Zaier; Saloua Yacoub Jemni; Testsuro Noguchi; Hagay Sobol; Zohra Soua
Journal:  Hered Cancer Clin Pract       Date:  2011-09-21       Impact factor: 2.857

10.  Novel immune modulators used in hematology: impact on NK cells.

Authors:  Stephanie Krieg; Evelyn Ullrich
Journal:  Front Immunol       Date:  2013-01-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.